Cellectar Biosciences, Inc.
As of Oct 22, 2026, Cellectar Biosciences is in Stage 4, the downtrend phase, now in week 29 (since Mar 27, 2026). It closed at $1.17, 71.0% below its 52-week high and below its 200-day average, which is falling.
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is CLRB early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
CLRB among Biotechnology434th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …434 | CLRB | Stage 4 · wk 29 | 14 | −44.0% |
Cellectar Biosciences: quick answers
What stage is Cellectar Biosciences in?
As of Oct 22, 2026, Cellectar Biosciences (CLRB) is in Stage 4, the downtrend phase. It entered Stage 4 on Mar 27, 2026 and is in week 29. What the four stages mean
Is Cellectar Biosciences in an uptrend?
No. Cellectar Biosciences is in a Stage 4 downtrend. It trades 56.7% below its 200-day average, which is falling.
How far is Cellectar Biosciences from its 52-week high?
Cellectar Biosciences closed at $1.17 on Oct 22, 2026, 71.0% below its 52-week high of $4.04. Its 52-week low is $1.12.
How has Cellectar Biosciences performed over the past year?
As of Oct 22, 2026, Cellectar Biosciences is down 72.2% over the past year and down 66.3% so far in 2026.
Which sector and industry is Cellectar Biosciences in?
Cellectar Biosciences is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR 121125, an iodine-125 Auger-emitting radioconjugate program; and CLR 225, an actinium-225 based radioconjugate program. The company has collaborative with Orano Med to develop alpha emitter lead-212 conjugated to phospholipid ether series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.